Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an update.
Lumos Diagnostics has secured Medicare reimbursement coverage for its FebriDx® test from a sixth Medicare Administrative Contractor (MAC), CGS Administrators, which covers Kentucky and Ohio. This achievement means Lumos now has reimbursement coverage from six out of seven MACs, representing over 85% of US Medicare payment coverage, significantly expanding its access to the Medicare patient population. This development is a critical milestone for Lumos, as Medicare often sets a precedent for private insurance payors, and it demonstrates the company’s commitment to achieving nationwide access and broad clinical adoption of FebriDx.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid, point-of-care diagnostic technologies. The company focuses on developing solutions that integrate seamlessly into care pathways and deliver value to the broader health system.
Average Trading Volume: 1,344,693
Technical Sentiment Signal: Sell
Current Market Cap: A$20.58M
Learn more about LDX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue